Checkpoint Therapeutics reports FY2023 net loss of $51.8M; BLA resubmission for cosibelimab targeted by mid-2024

Checkpoint Therapeutics, Inc.

Net loss $51.8M ($3.17 per share) vs $62.6M ($7.09) in FY2022; no revenue.
Cash and equivalents $4.9M at Dec 31, 2023; Jan 2024 offering added $14.0M gross.
R&D expenses $43.6M, down from $49.8M; G&A flat at $8.7M.
CRL from FDA in Dec 2023 only cited CMO inspection issues; resubmission planned mid-2024.
Appointed Dr. Amit Sharma to board; raised ~$47.6M via offerings in 2023-2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Checkpoint Therapeutics, Inc. reported full-year ended December 31, 2023 results: net income Net loss attributable to common stockholders for the year ended December 31, 2023, was $51.8 million, EPS ($3.17 per share).

Period: full-year ended December 31, 2023
Net income: Net loss attributable to common stockholders for the year ended December 31, 2023, was $51.8 million
EPS: ($3.17 per share)
Result: reported results

Exact text from the filing

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001104659-24-037602

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.